Worldwide public policies for celiac disease: are patients well assisted?

Objectives To evaluate public policies (PP) to celiac disease (CD) patients and classify countries regarding the level of assistance provided by the Public Policies for Celiac Disease Score. Methods Countries were scored from 0 to 6 according to the existence of PP regarding industrial food and meal...

Full description

Saved in:
Bibliographic Details
Published in:International journal of public health Vol. 65; no. 6; pp. 937 - 945
Main Authors: Falcomer, Ana Luísa, Luchine, Bruna Araújo, Gadelha, Hanna Ramalho, Szelmenczi, José Roberto, Nakano, Eduardo Yoshio, Farage, Priscila, Zandonadi, Renata Puppin
Format: Journal Article
Language:English
Published: Cham Springer International Publishing 01-07-2020
Springer Nature B.V
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To evaluate public policies (PP) to celiac disease (CD) patients and classify countries regarding the level of assistance provided by the Public Policies for Celiac Disease Score. Methods Countries were scored from 0 to 6 according to the existence of PP regarding industrial food and meal regulations, health service support, food allowance/financial incentive, gluten-free (GF) food certification, and CD associations. Subsequently, countries were allocated to continents. In total, 192 countries are registered as members of the World Health Organization. Results The European continent (score 3.63) is the most advanced in CD patient care, followed by South America (2.86), North America (1.05), Asia (0.53), Oceania (0.5), and Africa (0.27). Industrial food regulations were the most frequent PP (40.6%). 15.6% of the countries display regulations for meals; 13.5% have health service support; 13.5% have policies of food allowance/financial incentive; 19.3% have GF certification; and 34.4% have celiac associations. Conclusions Policies regarding GF meals and food safety certification, health service support, and financial incentives need improvement to ensure correct treatment and reduce the diseases’ financial burden for celiac patients and governments.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1661-8556
1661-8564
DOI:10.1007/s00038-020-01451-x